Nicholas Jacobus

Roche strengthens its pipeline by acquiring 89bio and its promising MASH treatment, Pegozafermin, enhancing options for metabolic disease therapies.

Rob DeWig, Vice President of Healthcare Sales, Inmar, touches on the impact of Inmar and Premier's expanded agreement on the broader healthcare and pharmacy ecosystems.

In today’s Pharmaceutical Executive Daily, we cover Lilly’s orforglipron as a prime candidate for FDA fast-track approval, Merck and Daiichi Sankyo’s breakthrough therapy designation for R-DXd in ovarian cancer, and Novo Nordisk’s EU approval of Rybelsus for reducing cardiovascular risk.

FDA warns major pharmaceutical companies to improve transparency in drug advertising, addressing misleading claims and enforcing stricter regulations.

VarmX partners with CSL to advance VMX-C001, a groundbreaking treatment for patients on FXa DOACs, enhancing surgical outcomes and patient care.

Eli Lilly's Orforglipron shows superior results in glycemic control and weight loss compared to oral semaglutide in recent clinical trials.

In today’s Pharmaceutical Executive Daily, we cover AbbVie’s stock jump following a Rinvoq litigation settlement, new insights into the ROI of specialty pharmacy adherence programs, and a closer look at what true innovation in PBM management entails.

AllRock Bio secures $50 million to advance Roc-101, a promising treatment for pulmonary hypertension, aiming to transform patient care.

Novo Nordisk's Rybelsus gains EU approval for cardiovascular benefits, enhancing treatment options for type 2 diabetes and improving patient outcomes.

Eli Lilly's Orforglipron may become the first drug fast-tracked under the FDA's new program, promising quicker access for weight loss treatment.

In today’s Pharmaceutical Executive Daily, we cover Novo Nordisk’s return-to-office mandate from its CEO, the evolving COVID-19 vaccine landscape in 2025, and Capsida’s decision to halt a gene therapy trial following a patient death.

AstraZeneca pauses its £271 million Cambridge investment, reflecting growing concerns over the U.K.'s life sciences sector and government support.

Novartis partners with Monte Rosa Therapeutics in a $5.7 billion deal to develop innovative treatments for immune-mediated diseases using AI technology.

It seems there is no text provided for summarization. Please provide the text you'd like summarized, and I'll be happy to help!

In today’s Pharmaceutical Executive Daily, we cover the president’s call to lower drug costs for patients, the compliance and operational pressures facing pharmaceutical manufacturers, and a White House plan to restrict treatments discovered in China.

AbbVie’s stock surges 4.4% after securing 12 more years of exclusivity for Rinvoq, boosting sales projections and investor confidence.

Novo Nordisk urges employees back to the office while announcing 9,000 job cuts to streamline operations and enhance decision-making.

Helen Sabzevari, PhD, president and CEO of Precigen, explains how Papzimeos transforms clinical practice by establishing the first FDA-approved standard of care for recurrent respiratory papillomatosis (RRP), shifting treatment from repeated surgeries to an immunotherapy that addresses the root HPV infection, with future plans to expand into pediatric populations and redosing strategies.

Pharmaceutical Executive Daily highlights major industry shifts, including job cuts at Lundbeck and Novo Nordisk, and Trump's critique of drug advertising practices.

White House plans potential restrictions on Chinese-developed drugs, sparking lobbying from investors and pharmaceutical giants amid national security concerns.

Intercept Pharmaceuticals withdraws Ocaliva from the U.S. market following FDA concerns over safety and effectiveness for treating primary biliary cholangitis.

Merck withdraws from its London research facility, highlighting growing concerns over the UK's life sciences investment climate and industry competitiveness.

Helen Sabzevari, PhD, president and CEO of Precigen, reflects on how Papzimeos sets an important precedent for rare disease therapies, with its broad FDA label for all adult patients with recurrent respiratory papillomatosis (RRP) highlighting the potential for earlier intervention to prevent irreversible damage and establish new standards of care.

Helen Sabzevari, PhD, president and CEO of Precigen, discusses the FDA’s decision to grant full approval to Papzimeos without requiring a confirmatory trial, highlighting how strong safety, efficacy, and durability data supported a broad label for all adult patients with recurrent respiratory papillomatosis (RRP).

Discover key strategies for enhancing pharmaceutical sales, the impact of AI in training, and FDA updates on GLP-1 compounding regulations.

Helen Sabzevari, PhD, president and CEO of Precigen, explains how Papzimeos, developed using the company’s AdenoVerse platform, became the first FDA-approved therapy for adult patients with recurrent respiratory papillomatosi.

Novartis acquires Tourmaline Bio to enhance its cardiovascular pipeline with Pacibekitug, a promising anti-inflammatory therapy for ASCVD.

In this video interview, Helen Sabzevari, PhD, president and CEO of Precigen, discusses the background of Recurrent Respiratory Papillomatosis treatments that led to Papzimeos becoming the first FDA-approved therapy for Recurrent Respiratory Papillomatosis.

In today’s Pharmaceutical Executive Daily, we review the wave of pharmaceutical layoffs shaping 2025, highlight the latest Pharm Exec Top 50 company rankings, and cover BioNTech and Duality Biologics’ clinical trial success with BNT323.

Regeneron’s Phase III trials show promising results for new antibody treatments, offering rapid and lasting relief from cat and birch allergies.